Defibrillator Threshold Testing by Zaqqa, Munir
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 8
Defibrillator Threshold Testing
Munir Zaqqa
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/52594
1. Introduction
Since implantable cardioverter-defibrillators (ICDs) were first introduced, defibrillator
threshold (DFT) testing was considered an integral part of the implant procedure. Perform‐
ing DFT testing verifies the ability of the ICD in detecting and aborting the lethal arrhythmia
it was designed to treat. The process has evolved with the development of the ICD’s and the
expanding indications for their usage. Recent studies even questioned the need for DFT as‐
sessment. Currently this matter is controversial with no firm guidelines. In this chapter we
present the basic information on DFT testing, how to manage high DFT, and then discuss
the evidence for and against performing the test.
2. DFT concept
DFT testing is performed by inducing ventricular arrhythmia and then finding the minimal
amount of energy delivered by the ICD to defibrillate the myocardium back to sinus
rhythm. Central to the concept of determining the DFT, was the discovery since 1930, that
electrical shocks themselves can induce ventricular fibrillation (VF) [1]. By giving a shock
during the vulnerable period of repolarization, VF could be reproducibly induced. Ventricu‐
lar tachycardia (VT) may also be induced, but in a relatively small percentage of patients [2].
As the amount of energy delivered during the vulnerable period is increased, a threshold is
reached that does not induce VF [3]. This is called the upper limit of vulnerability (ULV) and
is proportional to DFT value [4-5]. This concept can be used as a surrogate for DFT [6-7].
Instead of inducing VF and checking the threshold at which it terminates, a different proto‐
col is used that delivers variable strengths of shocks during the vulnerable T-wave phase
and then establishes ULV. As compared to regular DFT test, ULV test is done during sinus
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rhythm and not during VF. Using this approach there is a need for more number of shocks,
but less number of times that VF are induced.
The threshold to terminate ventricular fibrillation with ICD’s is usually in the 5 to 30 J range.
It was the ability to reduce the energy requirements by 10 folds as compared to external de‐
fibrillator that made the ICD a reality [8]. Otherwise the size of the ICD would have to be
much bigger to store the needed energy for defibrillation. Although the threshold is ex‐
pressed in relation to the energy discharged by the ICD, in reality it is the voltage and its
duration that is the critical factor in defibrillation [9-10]. Duration has a relatively narrow
range to be effective (in the range of few milliseconds). To achieve this precise phase dura‐
tion of defibrillation, the capacitor discharge is truncated in either a tilt based formula which
truncates the discharge after a certain percentage of decay in the voltage has been reached,
or more simply in a time based manner after a certain time has elapsed. Voltage is usually in
the hundreds of volts range. If voltage is too low it may induce rather than terminate fibril‐
lation as explained earlier. High voltage (above 1000 Volts) is also not without its risks, as it
may result in stunning of the myocardium and subsequent electromechanical dissociation
[11-12]. The voltage wave form can be manipulated to make defibrillation more effective
and therefore require less energy. Biphasic wave, which is the standard now in ICD’s, has
reversal of the initial polarity. The initial wave results in charging of the cell membrane as a
result of the voltage gradient. The reversal which is termed “burping” is theorized to absorb
the initial energy and therefore avoid proarrhythmia [11-12]. The biphasic wave form can be
manipulated by changing the initial voltage, and by changing the duration and the ratio of
its waves. Different manufactures use different formulas in their devices, and some allow
changing of the parameters by the electrophysiologists in case of high DFT.
3. Performing DFT testing
Before doing DFT testing, consent should be taken from the patient explaining the risk and
benefit of the procedure. Vital signs should be stable and basic lab results such as electro‐
lytes should be within normal range. There should be no contraindication to performing the
test such as severe aortic stenosis or intracavitary thrombus. An external defibrillator should
be placed ready next to the patient, preferably with defibrillator patches attached to the pa‐
tient. As the shock is painful, adequate sedation or short anesthesia should be given with
careful monitoring of vital signs and saturation level [14].
After the device is implanted good lead position should be verified by X-ray. The lead is
tested to ensure adequate sensing and pacing thresholds and normal impedance values.
Prior to VF induction, the device is activated and programmed with the amount of energy to
be delivered. Ventricular fibrillation is usually induced via the device. There are several
methods of VF induction such as programmed ventricular stimulation, T wave shock, fast
burst pacing, or by applying low voltage direct current [15]. Following VF induction the pa‐
tient is monitored carefully until the device detects the arrhythmia and restores it back to
sinus rhythm. If the device fails, external defibrillation should be immediately performed.
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To find the exact DFT value, this process has to be repeated several times with either a step
up, step down, or a binary fashion until DFT or ULV are found [16-17]. Although the term
threshold should indicate a value above which defibrillation is successful and below which
shocks fail, in reality DFT is a probabilistic phenomenon with a certain percentage of success
rate [17-18]. One shock may be successful while a successive one with the same conditions
may fail [5]. Despite the poor reproducibility of DFT, it is still a useful parameter, as this val‐
ue taken with a safety margin above it, gives a high clinical success of VF termination. The
standard safety margin is 10 J, although 5 J may be enough [19-20].
DFT testing with several shocks and titrations may be useful in a research protocol, where
the exact value has important clinical significance. A simpler, yet safe approach is the defib‐
rillator safety margin (DSM) test [21]. In this method, a single or two VF inductions may be
enough. The device is usually programmed to a value that is expected to restore sinus
rhythm following induction. This value depends on the operator preference. It is usually an
average value that is at least 10 J below the maximum output of the device [22]. If it is suc‐
cessful, then this value should at least be equal to the DFT value. If the shock fails, then step
up approach has to be used to find the threshold.
Study Year N Percent
Kelly et al [23] 1988 94 5.3%
Winkle et al [24] 1989 270 2.6%
Pinski et al [25] 1991 125 18%
Epstein et al [26] 1992 1946 4.6%
Gold et al [27] 1997 114 8%
Brodsky et al [28] 1999 764 3.1%
Shukla et al [29] 2003 968 11%
Russo et al [30] 2005 1139 6.2%
Theuns et al [31] 2005 127 14%
Mainigi et al [32] 2006 121 12%
Guenther et al [33] 2012 975 1.4%
Cheng et al [34] 2012 243 5.3%
Table 1. Incidence of high DFT
High DFT, defined in most studies as a threshold of < 10 J below the maximum output of the
device, is estimated to occur in about 5% of ICD implants (range 1.4 to 18%) (Tables 1)
[23-33]. Although the exact value of DFT cannot be predicted in an individual patient prior
to testing, there are some clinical parameters associated with increased thresholds (Table 2)
[27-29,32-35].
Defibrillator Threshold Testing
http://dx.doi.org/10.5772/52594
123
Young age
Low ejection fraction
Hypertrophic cardiomyopathy
Non coronary artery disease
Medications (specially amiodarone)
Larger and small left ventricular sizes
Large body size
Prolonged QRS duration
Table 2. Clinical factors associated with high DFT ‘s
DFT testing is usually performed introperatively at the time of implant before the pocket is
closed to allow intervention in case of high thresholds. Sometimes it is done at the time of
discharge or at a later time when the lead has assumed a stable position [28,36].
4. Management of high DFT
If a patient is found to have elevated thresholds, the initial step is to verify that this is not
caused by a reversible problem related to the implant procedure itself (table 3). If no reversi‐
ble cause is found, then there are several options available. These are classified into non-in‐
vasive and invasive methods (table 4).
Hypotension
Pneumothorax
Pericardial effusion
Large pleural effusion
Pulmonary edema
Sedation related such as aspiration and hypoxia
Acidosis
Electrolyte imbalance
Medications
Ischemia
Prolonged procedure
Lead dislodgment
Table 3. Reversible causes of high DFT
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Adjustment to improve DFT Comment
Non Invasive
Medications [37-41] Particularly amiodarone has been shown to increase thresholds.
Medications that potentially decrease thresholds include sotalol and
dofetilide.
Lead Polarity [43-44] The RV lead is the anode (positive) vector. It may be changed to cathode
(negative).
Vector of defibrillation [41,45] Adding an SVC coil is most effective when a single coil has high
resistance of > 58 ohm. If dual coil system is implanted, the vector can
be changed electronically.
Wave form [41,46] Change of Tilt and phase duration of shocks is available in some devices
and may be optimized individually.
Invasive
Lead repositioning [47-48] Apical position has lower DFT when compared to a proximal position.
Septal and RVOT positions may have lower thresholds
Addition of extra leads to change the vector
of the shock [49-51].
Subcutaneous array, coronary sinus and azygous vein leads could be
introduced to lower thresholds
Upgrading to higher output device
Table 4. Approaches to improve DFT
Changing or stopping a medication associated with high threshold may help the problem
[37]. Amiodarone has been particularly quoted in the literature as causing high thresholds
[38]. Other possible medications include lidocaine and verapamil. On the other hand, medi‐
cations that do not affect or potentially reduce DFT include sotalol, dofetilide, beta-blocker
and dronedarone [37-40].
There are some programmable parameters in the ICD that can affect DFT. These include po‐
larity of the lead, the vector of defibrillation, and the tilt and duration of the shock wave
[41-42]. The lead is configured with an anodal (positive) distal coil. This configuration re‐
sults in an average reduction of 15% in DFT as compared to a cathodal right ventricular (RV)
coil [43]. Reversing it to cathode results in the energy propagating away from the lead in‐
stead of “collapsing” towards it. This is theorized to increase the arrhythmia potential. How‐
ever, changing polarity has been shown to decrease DFT in some of the patients and this
configuration can therefore be attempted [44].
A dual-coil, active pectoral lead system is the most commonly used configuration. A proxi‐
mal coil placed in the superior vena cava (SVC) area has been found to decrease DFT as
compared to a single coil system [41,45]. This effect is particularly effective when the single
coil resistance is high (above 58 ohm), while the effect on the threshold is mixed with low
single coil resistance. Control of proximal coil can be done electronically in a dual coil lead.
Addition of an SVC coil might be considered in patients with single coil and high resistance.
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The proximal coil location should be in the high SVC and brachiocephalic area rather than
the low SVC and atrial area as the later is associated with higher DFT value [45].
The phase duration of defibrillation is critical in achieving sinus rhythm [9-10]. The optimal
phase duration is not exactly known and it can be optimized in some devices for individual
patients with high DFT’s [46].
Changing a nominal parameter should not be taken lightly, as these are the ones tested and
proven with clinical research. Any adjustment made to the settings should be verified by re‐
peated induction and the reassurance of a successful defibrillation.
Several invasive choices that reduce DFT are available. Changing the RV lead location may
reduce DFT. The standard RV position is the RV apex. This has the advantage of a stable
position and good threshold. Alternative lead positions that have good thresholds are the
right ventricular outflow tract (RVOT) and the septum. An active fixation system should be
used in these areas. A right free wall position has the highest DFT [47-48]. Changing the
shock vector may lower DFT. This can be achieved by incorporating subcutaneous array or
an additional lead in the azygous vein or the coronary sinus [49-51]. Upgrading to higher
output devices may be useful in patients with borderline elevated thresholds.
5. The arguments for and against performing DFT testing
Since implanting ICD’s in the early 1980’s, VF induction and testing the device ability to re‐
store sinus rhythm not only helped in determining DFT’s, but also allowed testing of the
sensing capability of the device, the ability of the programmed algorithm to recognize the
arrhythmia, and the ability of the capacitors to deliver the stored energy. This was an impor‐
tant step in testing a new device that is designed to treat a lethal arrhythmia. Patients who
were found to have high threshold had intervention performed to attempt to lower the
DFT’s. If the thresholds could not be lowered then many physicians did not implant the de‐
vice. This was because of the concern that a shock might change a stable VT into VF and
then not be able to terminate it. There were several reports of increased mortality in patients
with high DFT and case reports of deaths due to failed defibrillation. [23,28,52-54] (table 5).
Intuitively, finding DFT will result in reduced mortality as it allows the recognition of pa‐
tients who will not respond to the shock and therefore find a subgroup of patients who need
further intervention. However, this matter is not so simple.
Testing involves induction of ventricular fibrillation in patients with significant heart dis‐
ease with a potential for morbidity and mortality. Complications associates with DFT test‐
ing include worsening heart failure, hemodynamic compromise, cerebrovascular accidents
and even deaths. In the Canadian Experience study by Bernie et al which looked at 19,067
patients, thirty five patients (0.18%) had serious complications [61]. The recognition of the
complications was coupled with improvements in the lead and defibrillator technology. In
addition, ICD use expanded considerably after studies showed its benefit not only in secon‐
dary but also in primary prevention of sudden death. This changed the risk benefit ratio of
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DFT testing. Several studies gradually emerged that questioned the need to find DFT (ta‐
ble 5). This lack of benefit of DFT testing shown in several studies may be explained by
several factors:
• The comparison of the mortality in patients who had DFT testing versus those who did
not have a test may be a biased by excluding unstable patients from DFT testing and in‐
cluding them in the non tested group.
• The comparison should include the morbidity and mortality associated with the test itself
and also the problems related to the intervention to reduce DFT. Even simple measures
such as changing a medication and reprogramming the ICD could have an impact on
mortality, not to mention possible complications associated with invasive interventions.
The shock itself done during the test may have an impact on patients with established car‐
diac disease. Defibrillation has been shown to increase troponin level [62]. Any shock,
even when inappropriate, has been associated with increased mortality [63].
• DFT does not predict future successful defibrillation in a reliable manner [18]. This may
be related to the probabilistic nature of the test. It has also been shown that DFT change
acutely and chronically [64-65]. This could result in the improvement of high DFT, but
may also result in a patient with normal DFT developing high thresholds with time. It is
estimated that about 29% of deaths in ICD recipients are still due to arrhythmias that
could not be terminated by the ICD [66].
• Ventricular fibrillation induced in the hospital is not the same as the real world arrhyth‐
mia. Induced VF tends to be more organized than spontaneous VF [67]. In the clinical set‐
ting, many patients have ventricular tachycardia rather than VF or even do not have any
arrhythmia at all during the lifetime of the implant [2,68-69]. For these patients DFT test
may be misleading or may not have any relevance at all.
It  is therefore important to have to prospective randomized study to give us a clear an‐
swer. One prospective, but not randomized study (SAFE-ICD) showed no benefit of DFT
testing [60]. The result of an ongoing study (SIMPLE trial) may give a more clear direc‐
tion once finished [70].
The approach to DFT testing has changed over time. A recent study in 111 Italian centers
over the period 2007 to 2010 involving 2,082 patients documented the trend change [71]. It
reported DFT testing to be performed in 38% of patients with the incidence declining annu‐
ally from 36% in 2007 to 28% in 2010. In 13% of centers, the test was performed routinely,
and in 38% it was not performed at all. The reasons for not performing DFT testing in this
survey were the policy of the center in 44%, a primary indication for the implant in 31% and
doing a device replacement in 15%. Not doing DFT testing can certainly make the ICD im‐
plant simpler. The simplification is not just related to the procedure itself, but starts with the
initial step of taking the consent from the patient. It is not a simple task to explain the risk to
the patient in a lay term without confusing him. A physician has to explain that after the
surgery has finished successfully, there will be a need to stop the heart; and that there is a
chance, even though very small, that he may have a problem like stroke or that we may not
be able to restore his heart to beat back again.
Defibrillator Threshold Testing
http://dx.doi.org/10.5772/52594
127
Author Year N Comment
Favor DFT testing
Marchlinski et al [54] 1988 33 Patients with low DFT (n=19) had 100% success rate of clinical
arrhythmia termination as compared to 73% (n=14) in the high
threshold group
Pires et al [22] 2006 835 Long term survival was lower in the no DFT testing group (n=203) in
comparison to DFT and safety margin testing (n=632)
Hall et al [55] 2007 112 Higher mortality seen in patients who did not have DFT testing
because of contraindication (n=55) as compared to a random sample
who had DFT testing performed (n=57)
Against DFT testing
Epstein et al [26] 1992 1946 There was improved mortality among patients with high DFT who
received ICD (n=71) versus those who did not receive ICD (n=16)
Russo et al [30] 2005 1139 No difference in mortality among patients with high DFT who had
intervention (n=34) versus who did not have intervention (n=37)
Blatt et al [56] 2008 717 No difference in mortality between lower (< or =10 J) (n=547) versus
higher (n=170) DFT groups
Bianchi et al [57] 2009 291 No difference in mortality between Italian centers that perform DFT
testing routinely (n=137) versus centers that do not perform DFT
testing (n=154)
Michowitz et al [58] 2011 256 No difference in mortality between CRT-D patient who had DFT
testing (n=204) versus who did not have DFT testing (n=52)
Codner et al [59] 2012 213 No difference in mortality between DFT testing (n=80) and no DFT
testing (n=133) groups
Brignole et al [60] 2012 2120 Prospective but non randomized evaluation of DFT testing (n=836)
versus no DFT testing (n=1284) showed no difference in mortality
Table 5. Studies favoring and against DFT testing.
6. Conclusion
The approach to DFT testing has changed since ICD’s were first introduced. It has changed
from being an essential part performed in all the patients to being done in less than one
third of the patients at current time. The need for DFT testing is a balance between benefit
and risk with studies showing conflicting results. Most recent studies show equal benefit
risk ratio for DFT testing. A prospective randomized study is needed to resolve the issue
and there is currently one being performed. When this study is finished it should give a
more clear answer regarding this issue.
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